GALWAY, IRELAND--September 12, 2018--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Novartis is planning to build a new production plant for cell and gene therapies at its Stein site in Switzerland following approval for its chimeric antigen receptor T cell (CAR-T) cancer drug Kymriah by the European Commission (EC).

Within this article: Details plant addition, investment, timeline, cancer drug approval and related drug production

Login to Read More